Jitendra Kanodia
VP, Clinical Pharmacology & Translational Biology Xencor
Seminars
Wednesday 1st April 2026
Transforming IBD Treatment Landscape with Anti-TL1A Based Next Generation Monospecific and Multi-specific Antibodies
10:00 am
- Mechanistic advantages of long-acting anti-TL1A antibodies, including optimized stability, half-life, route of administration and tissue targeting to potentially enhance efficacy and durability
- Early-stage bispecific TL1A antibodies in preclinical development, designed to address multiple disease pathways simultaneously
- Translational strategies for integrating precision medicine approaches in IBD, laying the groundwork for future patient-stratified therapy
